Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bitcoin Falls Below $71,000 Data; Wormhole, Core Among Top Losers

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices trading below the key $71,000 level on Tuesday. Ethereum (CRYPTO: ETH) also edged lower, but remained above the key $3,600 mark this morning.
byAvi Kapoor
April 9, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices trading below the key $71,000 level on Tuesday.

Ethereum (CRYPTO: ETH) also edged lower, but remained above the key $3,600 mark this morning.

Toncoin (CRYPTO: TON) was the top gainer over the prior 24 hours, while Wormhole (CRYPTO: W) turned out to be the biggest loser.

At the time of writing, the global crypto market cap fell to $2.66 trillion, recording a 24-hour decline of 1.4%. BTC was trading lower by 2.2% at $70,868 while ETH fell by around 0.1% to $3,638 on Tuesday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

 

Toncoin (CRYPTO: TON)
Price: $6.89
24-hour gain: 18%

Ethena (CRYPTO: ENA)
Price: $1.28
24-hour gain: 14.6%

Nervos Network (CRYPTO: CKB)
Price: $0.03313
24-hour gain: 14.4%

Neo (CRYPTO: NEO)
Price: $19.99
24-hour gain: 12.1%

Gala (CRYPTO: GALA)
Price: $0.06746
24-hour gain: 7%

Losers

 

Wormhole (CRYPTO: W)
Price: $0.8922
24-hour drop: 10.9%

Core (CRYPTO: CORE)
Price: $2.41
24-hour drop: 10.4%

ORDI (CRYPTO: ORDI)
Price: $71.03
24-hour drop: 7.6%

Mantle (CRYPTO: MNT)
Price: $1.39
24-hour drop: 6.9%

Pepe (CRYPTO: PEPE)
Price: $0.000007353
24-hour drop: 6%

Read This Next: Neogen, Maxeon Solar Technologies And 3 Stocks To Watch Heading Into Tuesday

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

By Jelena Martinovic
May 16, 11:25 AM
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB